Delivery Order SPE2DR25D2205-SPE2DR26F2G16

<p>The Defense Logistics Agency issued a delivery order to AmerisourceBergen Drug Corp on February 25, 2026, for Visipaque 320 mg/ml infusion bottles (150 ml) with a ceiling value of $1,018.00.</p> <p>Place of performance is Conshohocken, PA. Ultimate completion date is February 26, 2026. The order is priced on a firm fixed-price basis with no set-aside applied.</p>

<p>The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on February 25, 2026, for Visipaque 320 mg/ml in 200 ml bottles, with a ceiling value of $1,812.88.</p> <p>Place of performance is Conshohocken, PA. The order is firm fixed price with an ultimate completion date of February 26, 2026. No set-aside was used.</p>

<p>The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on February 10, 2026, for Visipaque 320 mg/ml (100 ml bottles) with a ceiling value of $10,399.20 under firm fixed-price terms.</p> <p>Place of performance is Conshohocken, PA. The order is due for ultimate completion by February 11, 2026. No set-aside was used.</p>

<p>The Defense Logistics Agency issued a $1,876.40 delivery order to Amerisourcebergen Drug Corp on February 27, 2026, for Visipaque 270 mg/ml, 100 ml bottles. The order is firm fixed price with an ultimate completion date of March 2, 2026. Place of performance is Conshohocken, PA.</p>

The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on February 24, 2026, for Visipaque 320 mg/ml in 100 ml bottles, with a ceiling value of $3,379.74. Place of performance is Conshohocken, PA. Ultimate completion date is February 25, 2026. The order was issued under firm fixed-price terms with no set-aside. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., a major pharmaceutical distributor serving federal medical procurement needs through the Defense...

The Defense Logistics Agency awarded a $5,006.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Visipaque 320 mg/ml in 100 ml bottles. This contract, with an ultimate completion date of August 8, 2025, represents a non-set-aside competitive award for pharmaceutical procurement supporting federal medical supply needs. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...

The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Visipaque 320 mg/ml in 100ml bottles, valued at $1,001.34 under a Firm Fixed Price contract type. The award was made on October 8, 2025, with an ultimate completion date of October 9, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a non-competitive, competitively awarded transaction under an existing contract vehicle and does not utilize...

The Defense Logistics Agency awarded a $7,589.05 delivery order to AmerisourceBergen Drug Corp on January 22, 2026, for the supply of Visipaque 320 mg/ml infusion bottles (150ml). This is a firm fixed-price contract with an ultimate completion date of January 23, 2026, and represents a non-set-aside award issued under competitive procurement. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...

The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Visipaque 320 mg/ml infusion bottles (150 ml units) with a ceiling value of $4,126.40. This firm fixed-price delivery order, which is expected to be completed by August 20, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.9 billion through December 2026. The award was...

The Defense Logistics Agency (DLA) awarded a $2,859.78 firm fixed-price delivery order to AmerSourceBergen Drug Corp on January 16, 2026, for the procurement of Visipaque 320 mg/ml in 100ml bottles. This non-set-aside contract is scheduled for completion by January 20, 2026, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Visipaque is a contrast medium used in radiological and cardiovascular imaging procedures, representing a critical medical...